Market capitalization | $4.33m |
Enterprise Value | $4.01m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 401.00 |
P/S ratio (TTM) P/S ratio | 433.00 |
P/B ratio (TTM) P/B ratio | 4.00 |
Revenue growth (TTM) Revenue growth | 66.67% |
Revenue (TTM) Revenue | $10.00k |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
2 Analysts have issued a ZIOPHARM Oncology, Inc. forecast:
2 Analysts have issued a ZIOPHARM Oncology, Inc. forecast:
Mar '25 |
+/-
%
|
||
Revenue | 0.01 0.01 |
0%
0%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -4.16 -4.16 |
77%
77%
|
EBIT (Operating Income) EBIT | -4.16 -4.16 |
80%
80%
|
Net Profit | -4.07 -4.07 |
85%
85%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline include Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.
Head office | United States |
CEO | Dale Hogue |
Employees | 1 |
Founded | 2003 |
Website | www.alaunos.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.